$0.93
3.53%
Nasdaq, Fri, Oct 02 2026.
ISIN
US14817C1071
Symbol
SAVA

Cassava Sciences, Inc. Stock price

$0.93
+0.07 8.55% 1M
-0.80 46.19% 6M
-1.05 52.98% YTD
-2.50 72.86% 1Y
-15.87 94.46% 3Y
-53.38 98.29% 5Y
-6.28 87.09% 10Y
-43.23 97.89% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.03 3.53%
ISIN
US14817C1071
Symbol
SAVA
Industry

Is Cassava Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$106.1m
Shares outstanding
48.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
92.5%
Return on Equity
-16.7%
ROCE
-136.3%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$20.0m | -
SBC as % of FCF
-
SBC Growth 1Y
57.4%
Share Count Growth 1Y
0.7%
Shareholder Yield
-0.7%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-110.5m
EBIT
$-111.3m
Net Income
$-106.0m
Free Cash Flow | ex SBC
$-83.9m | $-103.9m
Growth
Revenue | estimate
- | -
EBITDA
17.2%
EBIT
17.4%
Net Income
-500.4%
Free Cash Flow
-7.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.2
FCF per Share
$-1.7
Short interest
14.9%
Employees
30
Rev per Employee
$0.0

Cassava Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cassava Sciences, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Cassava Sciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Cassava Sciences, Inc.

Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 68 68
2% 2%
-
- Research and Development Expense 43 43
36% 36%
-
-111 -111
17% 17%
-
- Depreciation and Amortization 0.80 0.80
33% 33%
-
EBIT (Operating Income) EBIT -111 -111
17% 17%
-
Net Profit -106 -106
500% 500%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cassava Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Head office United States
CEO Mr. Barry
Employees 30
Founded 1998
Website www.cassavasciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today